WO 2005/032475 PCT/US2004/032147

WE CLAIM

1. Immunogenic composition comprising NY-ESO-1 protein and a saponin based adjuvant.

- 2. The immunogenic composition of claim 1, wherein the NY-ESO-1 protein has the amino acid sequence SEQ ID NO: 1
- 3. The immunogenic composition of claim 1, wherein said saponin based adjuvant further comprises sterol.
- 4. The immunogenic composition of claim 3, wherein said saponin based adjuvant is an ISCOM or an ISCOMATRIX adjuvant
- 5. The immunogenic composition of claim 1, in an intramuscular dosage form.
- 6. The immunogenic composition of claim 1, in an intradermal form.
- 7. An isolated peptide comprising at least amino acids 89-99 of NY-ESO-1 and consisting of no more than amino acids 85-102 of NY-ESO-1.
- 8. The isolated peptide of claim 7, wherein said peptide binds to and is presented by an MHC molecule.
- 9. The isolated peptide of claim 8, wherein said peptide binds to an MHC molecule, wherein said MHC molecule is a class II molecule, and stimulates CD4⁺ cells when bound to said MHC class II molecule.
- 10. The isolated peptide of claim 9, wherein said MHC molecule is an HLA molecule.
- 11. The isolated peptide of claim 10, wherein said HLA molecule is an HLA-DR molecule.
- 12. An isolated peptide consisting of amino acids 89-100 of NY-ESO-1.
- 13. An isolated peptide consisting of amino acids 86-99 of NY-ESO-1.
- 14. A method for stimulating a T cell response, comprising contacting a T cell containing sample with a complex of the peptide of claim 7 and the MHC molecule to which it binds, under conditions favoring stimulation of a T cell response.

WO 2005/032475 PCT/US2004/032147

15. The method of claim 14, wherein said MHC molecule is a class II molecule, and said T cell response is a CD4⁺ T cell response.

- 16. The method of claim 15, wherein said MHC molecule is an HLA molecule.
- 17. The method of claim 16, wherein said HLA molecule is an HLA-DR molecule.
- 18. A method for stimulating a T cell response, comprising contacting a T cell containing sample with a complex of the peptide of claim 11 and the MHC molecule to which it binds, under conditions favoring stimulation of a T cell response.
- 19. A method for stimulating a T cell response, comprising contacting a T cell containing sample with a complex of the peptide of claim 12 and the MHC molecule to which it binds, under conditions favoring stimulation of a T cell response.
- 20. A method for treating a subject suffering from or in need of prophylaxis for a cancer, cells of which express NY-ESO-1, comprising administering to said subject an amount of a composition containing NY-ESO-1 protein and a saponin based adjuvant, sufficient to induce an antibody response to NY-ESO-1 in said subject.
- 21. The method of claim 20, wherein the amount of said compositions is sufficient to induce both a CD4⁺ and a CD8⁺ T cell response.
- 22. The method of claim 20, comprising administering said composition intramuscularly or subcutaneously.
- 23. The method of claim 20, wherein said saponin based adjuvant further comprises sterol.
- 24. The method of claim 20, wherein said saponin based adjuvant is an ISCOM or an ISCOMATRIX adjuvant.
- 25. The method of claim 20, comprising administering equal amounts of NY-ESO-1 and saponin based adjuvant to said subject.
- 26. The method of claim 20, comprising administering from about 10 to about 500μg of NY-ESO-1 protein to subject.

WO 2005/032475 PCT/US2004/032147

27. The method of claim 20, wherein said subject is affected with a tumor.

- 28. A method for stimulating an immune response comprising administering the immunogenic composition of claim 1 to a subject in need thereof in an amount sufficient to generate an immune response.
- 29. The method of claim 28, wherein said immunogenic response comprises an antibody response.
- 30. The method of claim 28, wherein said immunogenic response comprises a T cell response.
- 31. The method of claim 28, wherein said immunogenic response comprises an antibody and a T cell response.
- 32. The method of claim 28, comprising administering about 100 µg of NY-ESO-1 to said subject.
- 33. The method of claim 28, comprising administering said composition intramuscularly or intradermally.